Faecalibacterium Prausnitzii

In adult stool, what older assays called Faecalibacterium prausnitzii can be one of the most abundant fiber-fermenting signals. The organism gets attention because it turns dietary fiber into butyrate, the short-chain fat your colon lining burns as fuel.

When the gut becomes inflamed, this signal often falls. In one qPCR study of active inflammatory bowel disease, fecal levels in active Crohn's disease were far lower than in healthy controls. That is the pattern to understand: this is not a disease label, but a stool signal that often drops when the gut ecosystem is under stress.

What This Test Actually Measures

The assay uses PCR, a lab technique that copies a specific stretch of bacterial DNA until there is enough to count. It reports how much F. prausnitzii DNA is present per gram of stool, or what share of the total bacteria it represents.

Two things about that number deserve your attention. First, the test reads what is in your stool. That is not identical to what is living against your colon wall. Second, many assays target the 16S rRNA gene, a common bacterial ID tag. The DNA snippets used to start that test may not cleanly separate true F. prausnitzii from close relatives.

That second point matters more than it sounds. In one study of 580 Japanese adults, sequencing with a different gene target found that F. prausnitzii itself made up a median of only 1.48% of total Faecalibacterium in stool. F. taiwanense and F. longum were more abundant, and F. duncaniae was common too. That exact percentage comes from a single study, though a smaller study ranked the species the same way. If your lab uses broad 16S primers, part of what gets reported as F. prausnitzii may be a close relative.

Butyrate and the Colon Lining

Butyrate is the reason this bacterium gets so much attention. Your colon cells do something unusual: instead of running mostly on glucose like much of the rest of your body, they burn butyrate made by gut bacteria from fiber. F. prausnitzii is one of the main suppliers.

Beyond fuel, this species secretes a protein researchers call the microbial anti-inflammatory molecule. In laboratory and animal work it dampens NF-kB, a switch that turns on inflammatory genes. It also nudges the immune system toward regulatory T cells. These cells tell an immune response to stand down. Those mechanisms come from cell and animal studies, not from human trials, so treat them as the proposed explanation rather than proof of what happens in your gut. There is a naming wrinkle here as well: the reference strain behind much of that laboratory work, A2-165, has since been reclassified as Faecalibacterium duncaniae, so a large share of the foundational mechanistic evidence technically describes a close relative rather than F. prausnitzii itself.

The bacterium is also extremely oxygen-sensitive. Ordinary oxygen exposure is hard on it. That detail may help explain why it drops in inflamed tissue, where the inside of the gut can become more oxygen-rich than this organism likes.

Inflammatory Bowel Disease

This is where the evidence is strongest. A meta-analysis pooling 1,669 people, 427 with Crohn's disease, 560 with ulcerative colitis, and 682 controls, found substantial depletion in both major forms of inflammatory bowel disease, and the gap was larger for Crohn's disease than for ulcerative colitis. Levels fall further during an active flare than during remission. That same analysis concluded no diagnostic cutoff has been established.

The prognostic finding is more useful than the diagnostic one. In a study of people with ulcerative colitis in remission, those who had already stayed in remission for at least 12 months carried roughly two and a half times more of this bacterium in stool than those with shorter remission. Smaller follow-up data pointed in the same direction: recovery of the population went with maintained remission.

If you have inflammatory bowel disease and you are in remission, that is the useful part. A falling count is a signal worth bringing to your gastroenterologist before symptoms return, not after.

Sepsis Risk in the General Population

The strongest prospective evidence in people without gut disease comes from a Finnish population cohort of 6,372 adults followed for about 20 years, during which 240 people developed sepsis. People with more of this bacterium at baseline were less likely to develop sepsis over the following two decades. Each large step up in baseline abundance was linked to roughly a fifth lower risk, and the association held up in a separate validation cohort.

Read that carefully. It is an association from an observational cohort, not proof that the bacterium prevents sepsis. People with more of it also tend to eat more fiber, take fewer antibiotics, and be generally healthier, and the study cannot fully separate those. Still, it is the clearest long-horizon human outcome data this marker has, and it points in a coherent direction.

Colorectal Cancer

Depletion shows up in people with colorectal cancer, and specific sub-lineages of the species are lost in both cancer and colitis. But the more useful result for screening is what happened when researchers looked the other way around.

In an average-risk screening cohort where stool was collected in standard fecal immunochemical test tubes, F. prausnitzii levels on their own did not separate the people who turned out to have advanced lesions at colonoscopy. Total bacterial load did differ in those with cancer or high-grade dysplasia. So as a standalone cancer screen, this number is not doing the work.

Where it may earn its place is inside a ratio. In one case-control study, a Fusobacterium nucleatum-to-Bifidobacterium ratio caught about 85 out of 100 colorectal cancers while correctly clearing about 92 out of 100 people without cancer. Adding the Fusobacterium nucleatum-to-F. prausnitzii ratio improved classification of stage I disease in that study. The signal lives in the comparison, not the single number.

Skin, Fatigue, and Metabolic Conditions

Low levels also turn up in psoriasis, atopic dermatitis, obesity with fatty liver disease, and myalgic encephalomyelitis/chronic fatigue syndrome. In ME/CFS, lower abundance tracked with worse fatigue. In one human coronary artery disease cohort, higher levels went with lower circulating endotoxin. Endotoxin is a bacterial wall fragment that can drive inflammation when it leaks into the blood.

The breadth of that list is the problem, not the payoff. A marker that is low in Crohn's disease, psoriasis, fatty liver, chronic fatigue, and heart disease is telling you something general about inflammation and fiber fermentation, not something specific about which condition you have. Do not read a low result as a diagnosis of any of them.

Why a Single Reading Can Fool You

Recent antibiotics are the biggest distortion. Broad-spectrum regimens can slash this species, and a result drawn during or shortly after a course tells you about the antibiotic, not your baseline gut. Wait at least a month, and longer if you can.

There is no validated normal range. No professional body has set a cutoff for this test, and healthy people vary widely in what they carry. Your lab's reference band is a population distribution, not a target.

Two more things distort a reading. Stool is not mucosa, so what is measured in the toilet can differ from what is growing against your colon wall. And assay design matters: a 16S-based test and a species-specific test can produce meaningfully different numbers on the same sample, which makes comparing results across labs unreliable. Reported abundance also depends on whether the lab counts the whole Faecalibacterium genus or this one species, which is part of why published figures range from a few percent to well over ten percent of gut bacteria.

Why One Reading Is Not Enough

The absence of a validated cutoff is exactly why your own trend is the useful number. A single result sits in a wide healthy distribution with no line to cross. Two results, taken the same way at the same lab a few months apart, tell you direction, and direction is what you can act on.

The reason trending can work is that this species is often fairly stable within a person. It is scarce in early infancy, climbs through the first year as solid food replaces milk, and then tends to remain part of the adult gut community. When it does move, it can move quickly: fiber and prebiotics can shift it within days to weeks, and antibiotics can do the same in the other direction.

What to Do With an Unexpected Result

Interpret this number against its neighbors, never alone. Mucosal biopsy studies suggest that the balance between F. prausnitzii and E. coli separates gut inflammation patterns better than either does by itself. Stool panels are a looser version of that question. Add Akkermansia muciniphila and Roseburia to see whether the whole butyrate-producing and barrier-supporting community is down or just this one species.

If colorectal risk is the reason you are looking, remember the organism studied in cancer ratios was true Fusobacterium nucleatum, not just a genus-level Fusobacterium species result. The exact marker matters.

If your result is low and you have digestive symptoms, blood in stool, unexplained weight loss, or a first-degree relative with inflammatory bowel disease, the next test is fecal calprotectin. That measures immune cell activity in the gut wall. It is the marker that separates real inflammation from a microbiome that is simply short on fiber. A high calprotectin alongside a low count warrants a gastroenterologist and likely a colonoscopy.

If your result is low and you feel fine with normal calprotectin, the reasonable read is a diet-and-antibiotic story, not a disease. Recheck after a real change. If it stays low across repeated tests while your inflammatory markers stay clean, you may have a stable feature of your microbiome rather than a problem to chase.

How Mature Is This Test

This is a research-grade marker being sold clinically. No guideline body recommends it, no standardized cutpoints exist, and no professional society endorses it for screening asymptomatic people. Even the taxonomy is in flux: the organism was first described in 1922 under a different genus name, moved into Faecalibacterium in 2002, and has since been split into multiple species that older assays cannot tell apart.

That does not mean skip it. It means read it as one input into a picture, track your own trend rather than chasing a number, and let validated tests like calprotectin and colonoscopy carry the diagnostic weight.